Last updated on December 2016

Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Rheumatoid Arthritis
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    Participants with moderate to severe RA for whom the physician had decided to treat
    with golimumab according to the local product label, with the first dose being
    administered between 12 and 26 weeks prior to study enrollment
    Participants who have achieved an adequate therapeutic response to regular doses of
    golimumab, within 12 to 26 weeks of treatment
    Participants should be evaluated for tuberculosis (TB) exposure/risk factors or
    managed for active and latent TB (per local requirements and according to the local
    product label)
    Participants who have been evaluated for active/latent hepatitis B virus (HBV) and
    hepatitis C virus (HCV)
    Participants for whom, since golimumab initiation, a complete medical record is
    available

You may not be eligible for this study if the following are true:

  • Participants who have received and terminated golimumab treatment in the past
    Participants that have been treated with golimumab for more than 26 weeks prior to
    enrolment in the study
    Participants with use of any other investigational agent less than or equal to 30
    days before starting treatment with golimumab
    Participants with suspected latent TB, having not received prophylactic treatment of
    at least 4 weeks
    Participants with suspected or active TB
    Participants with active/latent HBV or HCV

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.